Association between serum albumin and 60-day mortality in Chinese Hakka patients with non-APL acute myeloid leukemia: a retrospective cohort study

Table 2 Multivariate Cox regression for ALB on 60-day mortality of AML

Variable	Non-adjusted Model		Model I		Model II		Model III
Variable	HR (95% CI)	P-Value	HR (95% CI)	P-Value	HR (95% CI)	P-Value	HR (95% CI)	P-Value
Serum ALB	0.91 (0.88 ~ 0.94)	< 0.001	0.93 (0.89 ~ 0.96)	< 0.001	0.92 (0.88 ~ 0.97)	0.001	0.94 (0.89 ~ 0.99)	0.015
Binary variable
ALB< 35 g/L	Ref.		Ref.		Ref.		Ref.
ALB≥35 g/L	0.47 (0.33 ~ 0.69)	< 0.001	0.59 (0.41 ~ 0.85)	0.005	0.57 (0.37 ~ 0.90)	0.015	0.55 (0.34 ~ 0.88)	0.013
Serum ALB quintile
Q1 (< 34.6 g/L)	Ref.		Ref.		Ref.		Ref.
Q2 (34.6–38.5 g/L)	0.56 (0.37 ~ 0.85)	0.006	0.64 (0.42 ~ 0.98)	0.038	0.57 (0.34 ~ 0.94)	0.038	0.50 (0.30 ~ 0.86)	0.012
Q3 ≥ 38.5 g/L)	0.32 (0.20 ~ 0.53)	< 0.001	0.44 (0.27 ~ 0.74)	0.002	0.40 (0.22 ~ 0.73)	0.002	0.47 (0.25 ~ 0.90)	0.022
P for trend		< 0.001		0.001		0.002		0.010

Notes: Model I: Adjusted for sex + age; Model II: adjusted for Model I + Glu + TBIL+ Myo + INR+ Fib+ SF + BM Blast+ FAB subtype+ Chemotherapy; Model III: Adjusted for Model II+ AST+ ALT+ Crea+ UA+ Hb + PLT + Genomic risk category + pulmonary infection+ EGOC performance-status score
Abbreviations: HR hazard ratio; CI confidence index; ALB albumin; Glu glucose; TBIL total bilirubin; Myo myoglobin; INR international normalized ratio; Fib Fibrinogen; SF Serum ferritin; BM bone marrow; FAB French, American, British; AST aspartate aminotransferase; ALT alanine aminotransferase; Crea creatinine; UA uric acid; Hb hemoglobin; Plt platelet; ECOG Eastern Cooperative Oncology Group

ISSN: 1471-2407